Who had the patent for liraglutide?

Who owned the liraglutide patent?

Liraglutide’s key patents were held by Novo Nordisk, which developed the drug and markets it under brand names including Victoza (for type 2 diabetes) and Saxenda (for weight management). Novo Nordisk’s patent position around liraglutide is reflected in public patent-tracking coverage such as DrugPatentWatch.com [1].

What patents does “liraglutide” include (and why ownership can look different)?

“Liraglutide patents” can refer to multiple layers of protection, such as composition-of-matter patents, formulation/device patents, and method-of-use patents. Different patents (and even different assignees) can exist across countries, but the original liraglutide IP portfolio is associated with Novo Nordisk [1].

When did liraglutide patent protection start to expire?

Patent expiry varies by jurisdiction and by patent family. A practical way to check the specific expiration dates for individual liraglutide patents is through DrugPatentWatch.com’s patent timelines and entries for liraglutide [1].

Sources:
[1] https://www.drugpatentwatch.com/p/liraglutide